Agilent helps uncover what causes diseases and how to treat them
In 2012, there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer worldwide. Although the number of cases is increasing, more people are surviving the disease. One reason is earlier detection and more effective drugs.
Agilent’s tools for analyzing DNA, RNA, proteins and metabolites have played an important role in the understanding and treatment of cancer. Agilent also works with pharmaceutical companies and researchers to advance treatment of cardiovascular disease and development disorders such as autism.
There are five major areas of pharma where Agilent helps customers gain new insights.
Finding out what causes the disease. Agilent’s genomic solutions, liquid chromatography (LC) and mass spectrometry (MS) platforms are used extensively to measure DNA, proteins and metabolites. Agilent’s GeneSpring Pathway Architecture software can pull data together from many sources. This helps pharma researchers understand the detailed molecular basis for disease.
Drug discovery. Agilent’s RapidFire MS product helps pharma scientists identify drugs that interact most strongly with desired targets. New biological drugs demonstrate many advantages over traditional chemical drugs, and Agilent is at the forefront of this trend.
R&D and drug development. Pharma labs must ensure that a new drug works, that it is safe and stable, and that its results are consistent and reproducible. Agilent LC, optical and MS solutions help pharma researchers validate their drug candidate – or as is often the case, realize it is time to go back to drug discovery. Agilent is also the leader in ultra-high-pressure liquid chromatography (UHPLC), which can acquire better data in less time.
Clinical trials. With a candidate drug now in hand, scientists want to know how well it will work on patients. With the acquisition of Dako, Agilent is now a leader in immunohistochemistry – a method of testing tumor tissue based on how it responds to various protein-based staining reagents. Agilent SureSelect Target Enrichment kits can also classify tumor properties, based on DNA sequencing.
Informatics and services. In a highly competitive industry, the management and protection of information about the next potential blockbuster drug is critical. Agilent’s OpenLAB software is used by 10 of the world’s top 11 pharmaceutical companies to create, collaborate, archive and re-use business-critical information easily and securely.
Agilent’s customer markets include energy and chemicals, food, the environment, forensics, pharmaceuticals, research and diagnostics.
For more information go to: